Aardvark Therapeutics Business Update
The FDA has lifted the clinical hold on Aardvark Therapeutics' Investigational New Drug (IND) application for ARD-101, which is being developed to treat hyperphagia in Prader-Willi Syndrome. The hold was originally placed in May 2026 following reversible ECG changes in healthy volunteers, but subsequent studies showed no cardiac events at therapeutic doses. The company plans to resume clinical development following further alignment with the FDA on Phase 3 trial design.
- Counterparty
- FDA